Baxter Encourages Canadians to Get Screened for Kidney Disease, to Understand the Risks and Therapy Options Available

Baxter Encourages Canadians to Get Screened for Kidney Disease, to Understand 
the Risks and Therapy Options Available 
Growing Rates of Chronic Kidney Disease Highlight Need for Increased Early 
Detection and Awareness of Treatment Options 
MISSISSAUGA, ON, March 13, 2013 /CNW/ - Along with the global kidney disease 
community, Baxter Corporation, a leader in dialysis treatment for more than 50 
years, is urging Canadians to learn about the symptoms and treatment options 
for chronic kidney disease on World Kidney Day, March 14. Early detection 
can lead to treatment options that help to maintain the health of your kidneys 
and reduce the risk of developing irreversible kidney failure. 
The incidence of chronic kidney disease (CKD) is growing, fuelled largely by 
diseases associated with an aging population, hypertension and increasing 
rates of diabetes. Worldwide, more than 353 million people (approximately 
5%) are living with chronic kidney disease(1,2), and 1.4 million people 
require renal replacement therapy(3). Studies show that 4 out of 5 people with 
advanced CKD (i.e. loss of over 50% of kidney function) do not know they have 
the disease(4). High-blood pressure and diabetes are two main risk factors for 
CKD(5), both of which are increasingly prevalent; with 1 in 3 adults worldwide 
having high blood pressure and 1 in 10 adults with diabetes(6). It is 
estimated that approximately 2.6 million Canadians have kidney disease or are 
at risk(7). 
"As the rate of CKD continues to grow in Canada with increasing numbers of 
patients requiring renal replacement, the need for early patient education 
about kidney disease and treatment options, including home-based treatments, 
has become critical," says Mike Oliver, General Manager, Baxter Corporation. 
Baxter is a proud supporter of World Kidney Day, a global health campaign of 
The International Society of Nephrology and the International Federation of 
Kidney Foundation that raises awareness about the importance of our kidneys 
and reducing the frequency and impact of kidney disease and its associated 
health problems. To help broaden awareness among Canadians, Baxter is also 
supporting a special insert on kidney disease developed by The Kidney 
Foundation of Canada and the Canadian Society of Nephrology, appearing in The 
Globe and Mail and La Presse on March 14 for World Kidney Day. 
"People with diabetes or hypertension, over the age of 60 or with a family 
history of kidney disease are at higher risk of progressing to chronic kidney 
disease. These patients should undergo screening and talk to their doctor 
about this disease regardless of whether they display symptoms or not," says 
Dr. Damien Belisle, nephrologist at CSSS de Chicoutimi. "Early detection of 
chronic kidney disease, by a simple blood and urine test, can dramatically 
affect how long you can preserve kidney function, what treatment options you 
have and the quality of life you will experience while living with the 
The human kidney works to remove waste and fluids from the body. As kidney 
disease progresses, the kidneys work less and less effectively. If detected 
early, lifestyle changes and selected medications can preserve kidney function 
for a longer period of time. If the disease progresses, in order to survive, 
people living with kidney disease must depend on renal replacement therapies 
to make up for lost kidney function, usually in the form of dialysis or 
transplantation. People may receive dialysis treatment at home (peritoneal 
or home hemodialysis), or in a dialysis center or hospital (in-center 
According to recent studies, chronic kidney disease patients who received 
early guidance from their nephrologist about their condition and dialysis 
treatment had a significantly lower risk of death within the first year of 
treatment(8,9). Studies have demonstrated that people living with kidney 
disease who are informed about treatment options and are given a choice more 
often choose a home therapy which presents opportunities for greater 
efficiencies and cost savings in the delivery of Canadian healthcare, provides 
better early survival(10), and can also provide a strong bridge to transplant 
for patients awaiting a replacement kidney(11,12). 
"We are committed to raising awareness for kidney disease and delivering the 
highest quality outcomes, by expanding the possibilities in dialysis, because 
patients deserve better," continues Oliver. "We continue to provide 
innovative, therapeutic firsts and to advocate for physicians and patients, to 
help remove the barriers that stand in the way of achieving optimal care." 
Understand the risks of kidney disease and the therapy options. Go to to learn more. 
About Baxter Renal Therapies
Baxter aims to offer patients the right therapy, at the right time, in the 
right setting, and believes in making the optimal therapeutic modality 
possible for more patients. As a global leader in renal replacement therapies, 
Baxter is committed to providing an innovative portfolio of products to 
deliver the highest quality outcomes. 
More than 50 years ago, Baxter pioneered lifesaving hemodialysis (HD) 
treatment for patients with end-stage kidney disease by introducing the first 
commercially built artificial kidney. Decades later, Baxter led the 
development of peritoneal dialysis (PD), a home-based alternative to the 
clinic-based HD treatment. Today, Baxter remains a leading manufacturer of 
products for PD, providing PD solutions, devices, related supplies and 
services to help patients perform dialysis treatment. Baxter also 
distributes products for hemodialysis, a therapy that generally takes place in 
a hospital or clinic. 
Baxter is also one of the largest industry supporters of dialysis research 
worldwide to stimulate scientific advancement, general knowledge in nephrology 
and innovation in dialysis care for patients. Most recently, Baxter invested 
in the PDOPPS and DOPPS research initiatives, which are designed to identify 
regional, national and facility-based practice patterns in the care of 
dialysis patients. This can contribute to enhanced patient survival, 
technique survival and quality of life. 
About Baxter
As the Canadian subsidiary of Baxter International Inc. (NYSE:BAX), Baxter 
Corporation manufactures and markets products that save and sustain the lives 
of people living with hemophilia, immune disorders, infectious diseases, 
kidney disease, trauma, and other chronic and acute medical conditions. As a 
global, diversified healthcare company, Baxter applies a unique combination of 
expertise in medical devices, pharmaceuticals and biotechnology to create 
products that advance patient care worldwide. More information: 
(1) Kidney Alliance, "Awareness of Kidney Disease is Low Despite it 
Affecting 500 million people worldwide" report,
(2) U.S. Census Bureau World PopClock Projection, "U.S. Census Bureau - 
World POPClock Projection".
(3) White, S, et. all, "How can we achieve global equity in provision of 
renal replacement therapy?" Bulletin of World Health Organization.
(4) Kidney Alliance, "Awareness of Kidney Disease is Low Despite it 
Affecting 500 million people worldwide" report,
(5) World Kidney Day,
(6) World Health Organization, World Health Statistics 2012,
(7) Kidney Foundation of Canada, FACING THE FACTS,
(8) Bradbury B.,, "Predictors of Early Mortality among Incident US 
Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study 
(DOPPS)," Clinical Journal of the American Society of Nephrology, no. 2 
(2007), 89-99.
(9) Hasegawa T., et. al., "Greater First-Year Survival on Hemodialysis in 
Facilities in Which Patients Are Provided Earlier and More Frequent 
Pre-nephrology Visits," Clinical Journal of the American Society of 
Nephrology, no. 4 (2009), 595-602.
(10) Yeates K, Zhu N, Vonesh E, Trpeski L, Blake P, Fenton S. Hemodialysis and 
peritoneal dialysis are associated with similar outcomes for end-stage renal 
disease treatment in Canada. Nephrol Dial Transplant. 2012:advance access.
(11) Schwenger V, Dohler B, Morath C, Zeier M, Opelz G. The role of 
pretransplant dialysis modality on renal allograft outcome. Nephrol Dial 
Transplant. 2011;26:3761-3766.
(12) Molnar MZ, Mehrotra R, Duong U, et al. Dialysis modality and outcomes 
in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:332-341. 
Media Contacts: Heather MacDonnell (905) 369-6398 
SOURCE: Baxter Corporation 
To view this news release in HTML formatting, please use the following URL: 
CO: Baxter Corporation
ST: Ontario
-0- Mar/13/2013 11:59 GMT
Press spacebar to pause and continue. Press esc to stop.